Cargando…
Antibody‐mediated enzyme formation: Its legacy at age fifty‐four
Antibody‐mediated enzyme formation is a phenomenon first described in 1968 and further studied by molecular Immunologists and Biochemists over the following five decades. The present review is made mainly by analyzing the 27 articles concerned with AMEF that appeared over the course of 47 years, com...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286546/ https://www.ncbi.nlm.nih.gov/pubmed/34693572 http://dx.doi.org/10.1002/jmr.2931 |
_version_ | 1784748036495245312 |
---|---|
author | Strom, Roberto Celada, Franco |
author_facet | Strom, Roberto Celada, Franco |
author_sort | Strom, Roberto |
collection | PubMed |
description | Antibody‐mediated enzyme formation is a phenomenon first described in 1968 and further studied by molecular Immunologists and Biochemists over the following five decades. The present review is made mainly by analyzing the 27 articles concerned with AMEF that appeared over the course of 47 years, commenting 16 original figures selected to be re‐printed in AMEF's Legacy. We, the reviewers, started by revisiting our own “insider's” experience of discovery, and followed by considering all results, our own and of members of other AMEF Labs. We had planned to conclude the review by correlating the various AMEF mutants to a detailed knowledge of the consensus betaGal structure. However, we became aware of several “robust” papers, published between 1989 and 2014, by authors outside of AMEF Labs. We familiarly called this surge: “The Second Wave” and adorned it with a doodle in Hokusai style. We were thrilled and happy to take them on board and properly examined their data. A team of this second wave had imagined unique uses for AMEF, and new doors to modern biotechnology. Another one had used AMEF as Tool and Marker to attain high levels of crystallography, solving puzzles of conformation, and ultimate structure. Together, they doubled our motivation to review AMEF. Serendipity gives us back the pleasure of finding, a treat at any age. |
format | Online Article Text |
id | pubmed-9286546 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92865462022-07-19 Antibody‐mediated enzyme formation: Its legacy at age fifty‐four Strom, Roberto Celada, Franco J Mol Recognit Review Antibody‐mediated enzyme formation is a phenomenon first described in 1968 and further studied by molecular Immunologists and Biochemists over the following five decades. The present review is made mainly by analyzing the 27 articles concerned with AMEF that appeared over the course of 47 years, commenting 16 original figures selected to be re‐printed in AMEF's Legacy. We, the reviewers, started by revisiting our own “insider's” experience of discovery, and followed by considering all results, our own and of members of other AMEF Labs. We had planned to conclude the review by correlating the various AMEF mutants to a detailed knowledge of the consensus betaGal structure. However, we became aware of several “robust” papers, published between 1989 and 2014, by authors outside of AMEF Labs. We familiarly called this surge: “The Second Wave” and adorned it with a doodle in Hokusai style. We were thrilled and happy to take them on board and properly examined their data. A team of this second wave had imagined unique uses for AMEF, and new doors to modern biotechnology. Another one had used AMEF as Tool and Marker to attain high levels of crystallography, solving puzzles of conformation, and ultimate structure. Together, they doubled our motivation to review AMEF. Serendipity gives us back the pleasure of finding, a treat at any age. John Wiley and Sons Inc. 2021-10-24 2021-12 /pmc/articles/PMC9286546/ /pubmed/34693572 http://dx.doi.org/10.1002/jmr.2931 Text en © 2021 The Authors. Journal of Molecular Recognition published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Review Strom, Roberto Celada, Franco Antibody‐mediated enzyme formation: Its legacy at age fifty‐four |
title |
Antibody‐mediated enzyme formation: Its legacy at age fifty‐four
|
title_full |
Antibody‐mediated enzyme formation: Its legacy at age fifty‐four
|
title_fullStr |
Antibody‐mediated enzyme formation: Its legacy at age fifty‐four
|
title_full_unstemmed |
Antibody‐mediated enzyme formation: Its legacy at age fifty‐four
|
title_short |
Antibody‐mediated enzyme formation: Its legacy at age fifty‐four
|
title_sort | antibody‐mediated enzyme formation: its legacy at age fifty‐four |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286546/ https://www.ncbi.nlm.nih.gov/pubmed/34693572 http://dx.doi.org/10.1002/jmr.2931 |
work_keys_str_mv | AT stromroberto antibodymediatedenzymeformationitslegacyatagefiftyfour AT celadafranco antibodymediatedenzymeformationitslegacyatagefiftyfour |